Refer to Difludiazepam.
It was originally developed by Hoffman-La Roche in the 1960s.
It is marketed in Japan and Taiwan. It exerts its pharmacological properties via enhancement of GABAergic inhibition.
Fludiazepam has 4 times more binding affinity for benzodiazepine receptors than diazepam. It possesses anxiolytic, anticonvulsant, sedative, hypnotic and skeletal muscle relaxant properties. Fludiazepam has been used recreationally.